To join this class action, please complete the following Investor Certification. 

[contact-form-7 id=”1842″ title=”Sesen Bio, Inc. Investor Certification”]

Oklahoma City, OK (September 24, 2021) – Federman & Sherwood reminds investors of the approaching deadline in the class action lawsuit against Sesen Bio, Inc. (NASDAQ: SESN) for potential securities law violations.  The allegations are of violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which December 21, 2020, to August 17, 2021.  More specifically, after the company announced their second quarter 2021 earnings, the shares of Sesen Bio traded up over 50% since the market opened on August 9, 2021. On August 13, 2021, Sesen Bio announced that the U.S. Food and Drug Administration (FDA) declined to approve the Company’s Biologics License Application (BLA) for its bladder cancer treatment Vicineum which resulted in a drastic drop in the stock.

The lawsuit seeks to recover damages on behalf of all Sesen Bio investors who purchased common stock during the Class Period and endured a loss. You may move the Court no later than October 18, 2021 to serve as a lead plaintiff for the entire Class. 

If you wish to obtain further information and participate in this or any other securities litigation, or should you have any questions regarding this notice or preservation of your rights, please contact:  Priscilla Scoggins at pms@federmanlaw.com